RESEARCH ARTICLE

Outcome of Rectal Cancer in Patients Aged 30 Years or Less in the Pakistani Population

Ali Akbar[1], Abu Bakar Hafeez Bhatti[1]*, Shahid Khattak[1], Aamir Ali Syed[1], Ather Saeed Kazmi[2], Aarif Jamshed[3]

Abstract

Background: The incidence of rectal cancer is increasing in younger age groups. Limited data is available regarding survival outcome in younger patients with conflicting results from western world. The goal of this study was to determine survival in patients with rectal cancer <30 years of age and compare it with their older counterparts in the Pakistani population. Materials and Methods: A retrospective chart review of patients operated for rectal adenocarcinoma between January 2005 and December 2010 was performed. Patients were divided into two groups, Group 1 aged ≤30years and Group 2 aged >30years. Patient characteristics, surgical procedure, histopathological details and number of loco-regional and distant failures were compared. Expected 5 year survival was calculated using Kaplan Meier curves and significance was determined using the Log rank test. Results: There were 38 patients in group 1 and 144 in group 2. A significantly high number of younger patients presented with poorly differentiated histology (44.7% *vs* 9.7%) (p=0.0001) and advanced pathological stage (63.1% *vs* 38.1%) (p=0.04). Predicted overall 5 year survival was 38% versus 57% in groups I and II, respectively (p=0.05). Disease free survival was 37% versus 52% and was significantly different (p=0.007). Conclusions: Early onset rectal cancer is associated with poor pathological features and a worse outcome in Pakistani population.

Keywords: Rectal cancer - survival - young age - older age - Pakistani patients

Asian Pac J Cancer Prev, **15 (15)**, 6339-6342

Introduction

Colorectal cancer (CRC) remains the second leading cause of cancer death in 21st century (Heidarnia et al., 2013). A downward trend was observed in the incidence of rectal cancer with an annual change of 2.7 percent in men and 2.1 percent in women between 2004 and 2008 (Eheman et al., 2012). In addition, mortality decreased by 35% from 1990 to 2007. This has been attributed to early diagnosis through screening and improvement in treatment modalities (Siegel et al., 2011). Rectal cancer generally has been a disease of old age with an average age at diagnosis around 65 years (El Mernissi et al., 2009). In recent years, presentation at an early age has become more common. An annual incidence increase of 2.6% in the 20-40 year age group has been observed in comparison with only 0.2 percent increase in colon cancer (O'Connell et al., 2004). This trend has also been observed in Asia (Atrkar-Roushan et al., 2013). It was shown recently by Abdifard and colleagues that colorectal cancer was on a rise in Iran possibly due to elevation of risk factors in this characteristic population (Abdifard et al., 2013). Rectal cancer in younger patients is more aggressive, diagnosed late, presents at an advanced stage and has poor differentiation. Thus the outcome in these patients is expected to be poor when compared with older counterparts (Adloff et al., 1986; Smith and Butler., 1989; O'Connell et al., 2004). Results however are limited and conflicting (Smith and Butler., 1989; Cusack et al., 1996). Surprisingly, there is no consensus on how young age rectal cancer is defined and age cut-offs like 45, 40 and 35 years have been used previously. In Pakistan, a high number of patients are diagnosed with rectal cancer at a young age but their outcomes have not been reported so far.

The objective of the current study was to determine disease free and overall survival in very young patients (age≤30) with rectal cancer and compare it with their older counterparts in our population.

Materials and Methods

A retrospective chart review of patients who underwent surgical resection for rectal cancer between January 2005 and December 2010 was performed. All patients with biopsy proven rectal adenocarcinoma were included in the study. Patients with squamous cell carcinoma, rectal gastrointestinal stromal tumors and metastatic disease

*[1]Department of Surgical Oncology, [2]Department of Medical Oncology, [3]Department of Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan *For correspondence: Abubakar.hafeez@yahoo.com*

were excluded. Patients with evidence of irresectable local disease on basis of clinical and radiological evidence were excluded from study.

Patients underwent extensive preoperative workup including colonoscopy, MRI pelvis for local and regional staging and CT scan chest, abdomen and pelvis for distant staging. All patients were discussed in multi-disciplinary team meeting and a treatment plan was formulated. Locally advanced resectable tumors were offered curative resection after neo-adjuvant induction chemotherapy with concurrent chemoradiotherapy or chemoradiotherapy alone. Pathological staging was performed based on American Joint committee on Cancer (AJCC) TNM classification. Patients were divided into two groups; Group I age≤30 years and Group II age 31 years and above.

Patient characteristics including age, gender, tumor grade, type, pathological variables and number of loco-regional and distant failures were compared. Operative information and details regarding neoadjuvant and adjuvant therapy were obtained from patient records. Chi square and Fischer's exact test were used for categorical variables. Disease free survival was calculated by subtracting date of recurrence from date of surgery. Overall survival was calculated by subtracting date of death or last follows up from date of surgery. Expected 5 year survival was calculated using Kaplan Meier curves and significance was determined using Log rank test.

Results

Patient characteristics

A total of 182 patients with rectal cancer underwent surgical resection. Out of these 38(20.8%) were≤30 years of age while 144 (79.1%) were>30 years. No significant difference in demographics, clinical stage and treatments offered was observed between the two groups as shown in (Table 1).

Table 1. Demographics and Treatment

		AGE>30 N=144	Percentage (%)	Age ≤30 (N=38)	Percentage (%)	Total	p value
Gender	Male	96	66.6%	24	63.0%	120	0.685
	Female	48	33.4%	14	37.0%	62	
Family history	Yes	7	4.8%	1	2.7%	8	0.12
	No	136	95.2%	37	97.3%	171	
Distance from anal verge(cm)	0-5	100	69.4%	25	65.7%	125	0.6
	6 to 10	38	26.3%	10	26.3%	48	
	More than 11	6	4.3%	3	8.0%	9	
Tumor stage	2	15	10.4%	2	5.2%	17	0.4
	3	97	67.3%	25	65.7%	122	
	4	32	22.3%	11	29.1%	43	
Preoperative nodal stage	0	21	14.5%	7	18.4%	28	0.18
	1	35	24.3%	4	10.6%	39	
	2	88	61.1%	27	71.0%	115	
Clinical stage	2	23	16.0%	7	18.5%	30	0.71
	3	121	84.0%	31	81.5%	152	
Treatment	IC given	70	48.0%	23	60.0%	93	0.19
	IC not given	74	52.0%	15	40.0%	89	
Procedure	APR	78	54.1%	16	42.1%	94	0.1
	LAR	45	31.2%	18	47.3%	63	
	ULAR	11	7.6%	4	10.6%	15	
	Others	10	7.1%	0	0.0%	10	
Access	Lap	80	55.5%	25	65.7%	105	0.44
	Open	49	34.0%	11	28.9%	60	
	Lap to open	15	10.5%	2	5.4%	17	

*LAR: Low anterior resection; APR: Abdominoperineal resection; ULAR: Ultra low anterior resection; IC: Induction chemotherapy

Table 2. Histopathological Variables

		Age >30 (N=144)	Percentage (%)	Age≤30 (N=38)	Percentage (%)	Total	p value
Grade	Well	30	20.8%	5	13.0%	35	0.001
	Moderate	95	65.9%	15	39.4%	110	
	Poor	14	9.7%	17	44.7%	31	
	Undifferentiated	5	3.6%	1	2.9%	6	
Mucinous	Yes	43	29.9%	26	68.5%	69	0.001
	No	101	70.1%	12	31.5%	111	
Pathological nodal stage	0	89	61.8%	14	36.8%	103	0.01
	1	25	17.3%	8	21.0%	33	
	2	30	20.9%	16	42.2%	46	
Pathological Tumor Stage	0	39	27.0%	6	15.7%	45	0.33
	1	7	4.8%	2	5.2%	9	
	2	24	16.6%	4	10.5%	28	
	3	64	44.4%	24	63.1%	88	
	4	10	7.2%	2	5.5%	12	
Pathological overall Stage	0	36	25.0%	6	15.7%	42	0.04
	1	22	15.2%	2	5.2%	24	
	2	31	21.5%	6	15.7%	37	
	3	55	38.3%	24	63.4%	79	

Table 3. Pattern of Recurrence

		AGE >30 (N=144)	Percentage (%)	Age≤ 30 (N=38)	Percentage (%)	Total	p value
Overall recurrence	Yes	51	35.5%	22	57.8%	73	0.01
	No	93	64.5%	16	42.2%	109	
Pattern of recurrence	None	93	64.5%	16	42.1%	109	0.1
	Local	15	10.4%	6	15.7%	21	
	Regional	2	1.3%	1	2.8%	3	
	Locoregional	5	3.8%	4	10.5%	9	
	Distant	29	20.0%	11	28.9%	40	
Status	Alive	79	54.8%	15	39.5%	94	0.09
	Dead	65	45.2%	23	60.5%	88	



Figure 1. Predicted 5 Year Overall Survival in Group 1 and 2 (p=0.05), 38% *vs* 57%



Figure 2. Predicted 5 Year Disease Free Survival In Group 1 and 2 (p=0.007), 37% *vs* 52%

Histopathological variables

A significant difference between two groups was present with respect to histology and differentiation. Younger patients were more likely to have poorly differentiated 17 (44.7%) and mucinous 26 (68.4%) tumors when compared with older counterparts (p<0.0001). Younger patients were also more likely to have nodal involvement when compared with the older group (p=0.01). Majority of young patients had advanced pathological stage i.e. (63 versus 38%) (p=0.04) as shown in (Table 2).

Survival

At 3.6 years of median follow up, 22(57.8%) patients experienced a recurrence in Group I while 51(35.4%) recurrences were observed in Group II (p=0.01) as shown in (Table 3). Median disease free survival was 1.8 (0.01-6.6) years and 1.2 (0.1-5.6) years for Group I and II respectively. Median overall survival was 3.8(.37-8.53) years and 2.46 (0.93-9.07) years for young and old groups. Predicted overall 5 year survival was 38% versus 57% in group I and II respectively. Although it was not statistically significant, a trend towards significance was observed (p=0.05). Disease free survival was 37% versus 52% in Groups I and II respectively and was significantly different (p=0.007) (Figure 1 and 2).

Discussion

Despite its frequent occurrence, little is reported about outcomes of rectal cancer in young patients from developing countries. The current study highlights significant differences in histopathology and adverse events between young and old age patients. A trend is observed for poor survival in younger patients. Limitations of the current study include its retrospective design and small number of patients in the age group less than 30.

The incidence of rectal cancer in the young is vastly variable and geographically tailored. It is as high as 10-23 percent in Asia and as low as 2.8-5.5 percent in the West (Adloff et al., 1986; Isbister., 1992; Chen et al., 1999; De silva et al., 2000; Alici et al., 2003; Keating et al., 2006).

However, studies have not used 30 years as the age cut-off. In most of the published studies age limit for young onset rectal cancer is 40 years (Domergue et al., 1988; Liang et al., 2003; Amin et al., 2012; You et al., 2012). Kansakar and colleagues attempted to determine changing trends in etiopathology in colorectal cancer patients in Nepal. Rectum was the most common site of primary and 28% patients belonged to 20-39 year age group. This distribution did not change over time (Kansakar and Singh, 2012). A 40 year cut-off is used since rectal cancer is predominantly a disease of old age and screening recommendations are generally developed for patients 40 years and above. We have used an age cut-off of 30 years. A close look at our data shows that 38.4% of our patients are 40 or younger. It has already been shown that around 30 percent patients in Pakistan are under 40 when diagnosed with rectal cancer (Bhurgri et al., 2011). The average life in Pakistan is low when compared to the west and would potentially make significant conclusions on survival difficult with higher age cut-offs.

In the current study, a high number of tumors in younger patients were poorly differentiated and of mucinous histology validating results of previously conducted studies (Smith and Butler., 1989; Chen et al., 1999; Liang et al., 2003). As reported by National Cancer Database, mucinous and signet ring histological subtypes occurred more commonly in patients with young-onset CRC (12.6% versus 10.8%)(You et al., 2012). Tumors were poorly differentiated in 27.3% of patients 20 to 40 years old versus 17.2% in patients in 60-80 years age group (p<0.001). In the current study, younger patients were more likely to present in stage III. This is also consistent

with previously conducted studies (O'Connell et al., 2004; Endreseth et al., 2006).

Variable outcomes have been reported for rectal cancers presenting at young age. Predicted survival of 38% at five years in the current study in younger patients is slightly low and can be due to high percentage of poorly differentiated, mucinous adenocarcinomas with advanced pathological stage. Studies with similar histopathological distribution in young age cancers have reported survival as low as 30% (Domergue et al., 1988, Smith and Butler., 1989). Recently, Haroon and colleagues reported on 23 patients with rectal cancer aged less than 40 years from Pakistan. Overall survival was not calculated and there was no comparison group (Haroon et al., 2013).

To our knowledge, this is the first study from Pakistan reporting 5 year disease free and overall survival in patients less than 30 years of age and comparing it with their older counterparts. Young age rectal cancer is a significant problem in our population and merits attention. This can be partially attributed to low average expected life in certain parts of Asia. Only 7.5% population in sub-continent was reported to be 60 years or above in comparison with 21% population in UK (Census of India., 2001; Census of England and Wales., 2001) We need to develop screening protocols designed to meet challenges of our characteristic patient population. There is a dire need to increase awareness in the community regarding significance of trivial signs and early presentation when disease is not advanced. This study highlights the characteristic age distribution and prognostic variables in young patients.

References

Adloff M, Arnaud JP, Schloegel M, Thibaud D, Bergarmaschi R (1986). Colorectal cancer in patients under 40 years of age. *Dis Colon Rectum*, **29**, 322-5.

Alici S, Aykan Faruk N, Sakar B, Bulutlar G, Kaytan E, et al (2003). Colorectal cancer in young pateints: characteristics and outcome. *Tohoku J Exp Med*, **199**, 85-93.

Amin TT, Suleman W, Al Taissan AA, et al (2012). Patients' profile, clinical presentations and histopathological features of colo-rectal cancer in Al Hassa region, Saudi Arabia. *Asian Pac J Cancer Prev*, **13**, 211-6.

Atrkar-Roushan Z, Kazemnejad A, Mansour-Ghanaei F, Zayeri F (2013). Trend analysis of gastrointestinal cancer incidences in Guilan province: comparing rates over 15 years. *Asian Pac J Cancer Prev*, **14**, 7587-93.

Abdifard E, Ghaderi S, Hosseini S, Heidari M (2013). Incidence trends of colorectal cancer in the west of Iran during 2000-2005. *Asian Pac J Cancer Prev*, **14**, 1807-11.

Bhurgri Y, Khan T, Kayani N, Ahmad R, Usman A, et al (2011). Incidence and current trends of colorectal malignancies in an unscreened, low risk Pakistan population. *Asian Pac J Cancer Prev*, **12**, 703-8.

Census of England and Wales (2001). Office for National Statistics http: //www.statistics.gov.uk/census 2001.

Census of India (2001). Register general & census commissioner, India. http://censusindia.gov.In

Chen HS (1999). Curative resection of colorectal adenocarcinoma: multivariate analysis of 5-year follow-up. *World J Surg*, **23**, 1301-1306.

Cusack JC, Giacco GG, Cleary K, et al (1996). Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. *J Am Coll Surg*, **183**, 105-12.

De Silva MV, Fernando MS, Fernando D (2000). Comparison of some clinical and histological features of colorectal carcinoma occurring in patients below and above 40 years. *Ceylon Med J*, **45**, 166-8.

Domergue J, Ismail M, Astre C, et al (1988). Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. *Cancer,* **61**, 835-840.

Eheman C, Henley SJ, Ballard-Barbash R, et al (2012). Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. *Cancer*, **118**, 2338-66.

El Mernissi H, Hrora A, Mrini K, et al (2009). Rectal cancer on young patient compared with elderly patient about a Moroccan hospital service experience. *Arab J Gastroenterol*, **10**, 29.

Endreseth BH, Romundstad P, Myrvold HE, et al (2006). Rectal cancer in the young patient. *Dis Colon Rectum*, **49**, 993-1006.

Haroon N, Khan S, Alvi R (2013). Rectal carcinoma under 40 years of age: seven-year post-treatment follow-up at a tertiary care hospital in Pakistan. *J Pak Med Assoc*, **63**, 1460-3.

Heidarnia MA, Monfared ED, Akbari ME, et al (2013). Social determinants of health and 5-year survival of colorectal cancer. *Asian Pac J Cancer Prev*, **14**, 5111-6.

Isbister WH (1992). Colorectal cancer Below Age 40 in The Kingdom of Saudi Arabia. *ANZ J Surg*, **62**, 468-472.

Keating J, Yong D, Cutler G, Johnstone J (2006). Multidisciplinary treatment of colorectal cancer in New Zealand: survival rate from 1987 to 2002. *NZ Med J*, **119**, 2238.

Kansakar P, Singh Y (2012). Changing trends of colorectal carcinoma in Nepalese young adults. *Asian Pac J Cancer Prev*, **13**, 3209-12.

Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, et al (2003). Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. *Br J Surg*, **90**, 205-14.

O'Connell JB, Maggard MA, Liu JH, et al (2004). Do young colon cancer patients have worse outcome? *World J Surg*, **28**, 558-562.

O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Ko CY (2004). Are survival rates different for young and older patients with rectal cancer? *Dis Colon Rectum*, **47**, 2064-9.

Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin*, **61**, 212-36.

Smith C, Butler JA (1989). Colorectal cancer in patients younger than 40 years of age. *Dis Colon Rectum*, **32**, 843-6.

You YN, Xing Y, Feig BW, et al (2012). Young-onset colorectal cancer: is it time to pay attention? *Arch Intern Med*, **172**, 287-9.